DENVER, May 5, 2020 /PRNewswire/ -- As part of its
continued efforts to further transform patient care, DaVita today
unveiled DaVita Venture Group (DVG). This group plans to accelerate
DaVita's efforts to develop and deploy solutions that are designed
to improve the health care and quality of life for people with
kidney disease and related chronic conditions.
"Innovation should never stop when there is an opportunity to
improve patient care," said Javier
Rodriguez, CEO of DaVita. "We want to transform kidney
health – from chronic kidney disease to transplant – and we're
putting financial and strategic resources into these solutions. We
believe we can be the partner of choice for entrepreneurs who want
to bring best in class technology and innovations to market."
For more than 20 years, DaVita has been a leader in creating
innovative, patient-centric care models that utilize the latest
technology designed to improve quality of life. Leveraging its
broad expertise, DVG identifies companies and products for
strategic partnerships, venture investment opportunities, and to
incubate transformative solutions. The group's focus includes
innovation in digital health, pharmaceuticals, medical devices, and
care delivery models. DVG contributes clinical and operational
knowledge and seeks to collaborate with other entities to develop,
test and bring new technologies to market.
"DaVita Venture Group aims to find new solutions for our
patients that go beyond dialysis," said Steve Phillips, vice president of innovation for
DVG. "We're excited to fund select venture capital investments in
early stage companies, which will have the potential to drive
innovation over time."
Bringing patient-centered chronic care to scale requires
reimagining health care as it exists today. A typical patient with
end-stage kidney disease is high-risk and high-need. They often
have four or more comorbidities and spend approximately 11 days in
the hospital each year. With a focus on broadening innovation
across the continuum, DVG aims to expand access to care and improve
clinical outcomes while also increasing the adoption of value-based
care to reduce costs.
"This is an exciting time in health care as entrepreneurs,
researchers and industry leaders envision solutions that could
change care delivery for the better," stated Mahesh Krishnan, group vice president of
research and development for DVG. "We believe we can help drive
that change, and that DaVita Venture Group is a great incubator to
help advance these solutions to market."
About DaVita Inc.
DaVita (NYSE: DVA) is a health
care provider focused on transforming care delivery to improve
quality of life for patients globally. The company is one of the
largest providers of kidney care services in the U.S. and has been
a leader in clinical quality and innovation for more than 20 years.
Through DaVita Kidney Care, the
company treats patients with chronic kidney failure and end stage
kidney disease. DaVita is committed to bold, patient-centric care
models, implementing the latest technologies and moving toward
integrated care offerings for all. Through these efforts, DaVita
has also become the largest provider of home dialysis in the
country. As of December 31, 2019, DaVita served 206,900
patients at 2,753 outpatient dialysis centers in the
United States. The company also
operated 259 outpatient dialysis centers in ten countries
worldwide. DaVita has reduced hospitalizations, improved mortality,
and worked collaboratively to propel the kidney care industry to
adopt an equitable and high-quality standard of care for all
patients, everywhere. To learn more,
visit DaVita.com/About.
Forward-Looking Statements
All statements in this
release, other than statements of historical fact, are
forward-looking statements and as such are intended to be covered
by the safe harbor for "forward-looking statements" provided by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on DaVita's current
expectations and are based solely on information available as of
the date of this release. DaVita undertakes no obligation to
publicly update or revise any forward-looking statements, whether
as a result of changed circumstances, new information, future
events or otherwise. Actual future events and results could differ
materially from any forward-looking statements due to numerous
factors that involve substantial known and unknown risks and
uncertainties. These risks and uncertainties include, but are not
limited to, those described in the risk factors set forth in DaVita
Inc.'s Annual Report on Form 10-K for the year ended December
31, 2019, and the risks and uncertainties discussed in any
subsequent reports that DaVita files or furnishes with the
Securities and Exchange Commission from time to time.
Contact Information
Media:
Halie Peddle
(303) 550-6349
Halie.Peddle@DaVita.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/davita-launches-venture-group-to-accelerate-advancements-in-kidney-care-301052568.html
SOURCE DaVita